77 related articles for article (PubMed ID: 21115895)
21. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
22. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
23. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
[TBL] [Abstract][Full Text] [Related]
26. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
Caney C; Singh G; Lukka H; Rainbow AJ
Int J Radiat Biol; 2004 Apr; 80(4):291-9. PubMed ID: 15204706
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
28. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
30. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
31. Combining radiation with oxaliplatin: a review of experimental results.
Hermann RM; Rave-Fränk M; Pradier O
Cancer Radiother; 2008 Jan; 12(1):61-7. PubMed ID: 18243751
[TBL] [Abstract][Full Text] [Related]
32. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
33. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
34. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.
Zamble DB; Jacks T; Lippard SJ
Proc Natl Acad Sci U S A; 1998 May; 95(11):6163-8. PubMed ID: 9600935
[TBL] [Abstract][Full Text] [Related]
35. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
[TBL] [Abstract][Full Text] [Related]
36. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling.
Topping RP; Wilkinson JC; Scarpinato KD
J Biol Chem; 2009 May; 284(21):14029-39. PubMed ID: 19286655
[TBL] [Abstract][Full Text] [Related]
38. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
39. Suppression of heat-induced p53 accumulation and activation by CDDP or x-rays in human glioblastoma cells.
Matsumoto H; Hayashi S; Shioura H; Ohtsubo T; Nishida T; Kitai R; Ohnishi T; Kano E
Int J Oncol; 1998 Oct; 13(4):741-7. PubMed ID: 9735404
[TBL] [Abstract][Full Text] [Related]
40. Induction of instability of p34(cdc2) expression by treatment with cisplatin (CDDP) in mouse teratocarcinoma F9 cells.
Doi T; Morita T; Wakabayashi N; Sumi T; Iwai SA; Amekawa S; Sakuda M; Nishimune Y
Cancer Lett; 2002 Feb; 176(1):75-80. PubMed ID: 11790456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
